Vol.

No.

September 11, 2020Sep 11, 2020

DOWNLOAD THE PDF

Cover Story

NCI will form an ad hoc committee to review screening trials

The future of ECOG-ACRIN's slowly-accruing TMIST is in question

By Paul Goldberg

NCI's cancer screening trials may be falling victim to the COVID-19 pandemic.

Conversation with The Cancer Letter

Mitch Schnall: “We don't want to lose momentum as this review is happening”

By Paul Goldberg

Guest Editorial

Toward individualized breast cancer screening strategies—TMIST

By Etta D. Pisano, Constantine A. Gatsonis, Peter J. O'Dwyer and Mitchell D. Schnall

Letter To The Editor

A reminder: The real goal is saving lives

By Frances M. Visco

Free Guest Editorial

An open letter to Sen. Kamala Harris

By Hooman Noorchashm

In Brief

Mays Cancer Center receives renewal of NCI designation

Justin Leung receives $1.9 million in funds to research DNA damage response

Surupa Sen Gupta joins Maryland Oncology Hematology

Clinical Roundup

JNCCN study sheds light on multi-organ adverse events from immunotherapy

City of Hope scientists combine oncolytic virus and CAR T in solid tumors

Phase II study of Tabrecta shows positive ORR for NSCLC

Drugs & Targets

Pralsetinib receives FDA approval for lung cancer with RET gene fusions

Oncomine Dx Target Test receives FDA approval as first NGS-based companion diagnostic for RET fusion + NSCLC

FDA issues alert about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer

Oncocyte receives final pricing decision for DetermaRx Molecular Test for lung cancer from CMS

MD Anderson, Xencor collaborate on investigational XmAb drug candidates

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

NCI will form an ad hoc committee to review screening trials

Mitch Schnall: “We don't want to lose momentum as this review is happening”

Toward individualized breast cancer screening strategies—TMIST

A reminder: The real goal is saving lives

An open letter to Sen. Kamala Harris

In Brief

Mays Cancer Center receives renewal of NCI designation

Justin Leung receives $1.9 million in funds to research DNA damage response

Surupa Sen Gupta joins Maryland Oncology Hematology

Clinical Roundup

JNCCN study sheds light on multi-organ adverse events from immunotherapy

City of Hope scientists combine oncolytic virus and CAR T in solid tumors

Phase II study of Tabrecta shows positive ORR for NSCLC

Drugs & Targets

Pralsetinib receives FDA approval for lung cancer with RET gene fusions

Oncomine Dx Target Test receives FDA approval as first NGS-based companion diagnostic for RET fusion + NSCLC

FDA issues alert about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer

Oncocyte receives final pricing decision for DetermaRx Molecular Test for lung cancer from CMS

MD Anderson, Xencor collaborate on investigational XmAb drug candidates

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login